Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 3-4/2023

13.01.2023 | case report

Ovarian yolk sac tumor in a premenarchal girl

verfasst von: Antonio Ivan Miletić, MD, Prof. Dubravko Habek, MD, PhD med. sc., PhD hum. sc., Filip Medić, MD, Matija Prka, MD, Sanja Berić Lerotić, MD, PhD, Prof. Fabijan Knežević, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2023

Einloggen, um Zugang zu erhalten

Summary

Yolk sac tumors are highly malignant and commonly affect the ovaries, with a median age of occurrence of 23 years. We describe the case of an ovarian yolk sac tumor in a 12-year-old premenarchal girl suffering from Hashimoto’s thyroiditis and chronic spontaneous urticaria, which presented as a rapidly growing solid cystic formation in the hypogastrium with an extreme increase in alpha fetoprotein (52,778 mg/ml). After ultrasound and MRI imaging, fertility-sparing staging surgery was performed, and the diagnosis of an ovarian yolk sac tumor with positive malignant cells in ascites was confirmed. The specificity of this case is the tumor classification into stage IC3 according to the FIGO and stage III according to the Children’s Oncology Group criteria. The postoperative course was complicated by a pelvic abscess and a subcutaneous suture rejection reaction. Our case may incite further research on the relationship between autoimmunity and yolk sac tumors.
Literatur
1.
Zurück zum Zitat Dällenbach P, Bonnefoi H, Pelte M‑F, Vlastos G. Yolk sac tumours of the ovary: an update. Eur J Surg Oncol EJSO 2006;32:1063–75. Dällenbach P, Bonnefoi H, Pelte M‑F, Vlastos G. Yolk sac tumours of the ovary: an update. Eur J Surg Oncol EJSO 2006;32:1063–75.
2.
Zurück zum Zitat Chen LH, Yip K‑C, Wu H‑J, Yong S‑B. Yolk Sac Tumor in an Eight-Year-Old Girl: A Case Report and Literature Review. Front Pediatr. 2019;7:169.CrossRefPubMedPubMedCentral Chen LH, Yip K‑C, Wu H‑J, Yong S‑B. Yolk Sac Tumor in an Eight-Year-Old Girl: A Case Report and Literature Review. Front Pediatr. 2019;7:169.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP, et al. Paediatric extracranial germ-cell tumours. Lancet Oncol. 2016;17:e149–62.CrossRefPubMed Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP, et al. Paediatric extracranial germ-cell tumours. Lancet Oncol. 2016;17:e149–62.CrossRefPubMed
4.
Zurück zum Zitat Park J‑Y, Kim D‑Y, Suh D‑S, Kim J‑H, Kim Y‑M, Kim Y‑T, et al. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2017;145:513–8.CrossRefPubMed Park J‑Y, Kim D‑Y, Suh D‑S, Kim J‑H, Kim Y‑M, Kim Y‑T, et al. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2017;145:513–8.CrossRefPubMed
5.
Zurück zum Zitat Guo Y‑L, Zhang Y‑L, Zhu J‑Q. Prognostic value of serum α‑fetoprotein in ovarian yolk sac tumors: A systematic review and meta-analysis. Mol Clin Oncol. 2015;3:125–32.CrossRefPubMed Guo Y‑L, Zhang Y‑L, Zhu J‑Q. Prognostic value of serum α‑fetoprotein in ovarian yolk sac tumors: A systematic review and meta-analysis. Mol Clin Oncol. 2015;3:125–32.CrossRefPubMed
6.
Zurück zum Zitat Prat J. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26:87.CrossRefPubMedPubMedCentral Prat J. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26:87.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, et al. Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. J Clin Oncol. 2004;22:2691–700.CrossRefPubMed Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, et al. Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. J Clin Oncol. 2004;22:2691–700.CrossRefPubMed
8.
Zurück zum Zitat Sevelsted A, Stokholm J, Bønnelykke K, Bisgaard H. Cesarean Section and Chronic Immune Disorders. Pediatrics. 2015;135:e92–8.CrossRefPubMed Sevelsted A, Stokholm J, Bønnelykke K, Bisgaard H. Cesarean Section and Chronic Immune Disorders. Pediatrics. 2015;135:e92–8.CrossRefPubMed
10.
Zurück zum Zitat Lock AM, Gao R, Naot D, Coleman B, Cornish J, Musson DS. Induction of immune gene expression and inflammatory mediator release by commonly used surgical suture materials: an experimental in vitro study. Patient Saf Surg. 2017;11:16.CrossRefPubMedPubMedCentral Lock AM, Gao R, Naot D, Coleman B, Cornish J, Musson DS. Induction of immune gene expression and inflammatory mediator release by commonly used surgical suture materials: an experimental in vitro study. Patient Saf Surg. 2017;11:16.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Chistiakov D, Turakulov R. CTLA‑4 and its role in autoimmune thyroid disease. J Mol Endocrinol. 2003;31:21–36.CrossRefPubMed Chistiakov D, Turakulov R. CTLA‑4 and its role in autoimmune thyroid disease. J Mol Endocrinol. 2003;31:21–36.CrossRefPubMed
12.
Zurück zum Zitat Lobo J, Rodrigues Â, Guimarães R, Cantante M, Lopes P, Maurício J, et al. Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA‑4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers. 2019;11:1535.CrossRefPubMedPubMedCentral Lobo J, Rodrigues Â, Guimarães R, Cantante M, Lopes P, Maurício J, et al. Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA‑4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers. 2019;11:1535.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hodroj K, Stevovic A, Attignon V, Ferraioli D, Meeus P, Croce S, et al. Molecular Characterization of Ovarian Yolk Sac Tumor (OYST). Cancers. 2021;13:220.CrossRefPubMedPubMedCentral Hodroj K, Stevovic A, Attignon V, Ferraioli D, Meeus P, Croce S, et al. Molecular Characterization of Ovarian Yolk Sac Tumor (OYST). Cancers. 2021;13:220.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol. 2021;14:101029.CrossRefPubMedPubMedCentral Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol. 2021;14:101029.CrossRefPubMedPubMedCentral
Metadaten
Titel
Ovarian yolk sac tumor in a premenarchal girl
verfasst von
Antonio Ivan Miletić, MD
Prof. Dubravko Habek, MD, PhD med. sc., PhD hum. sc.
Filip Medić, MD
Matija Prka, MD
Sanja Berić Lerotić, MD, PhD
Prof. Fabijan Knežević, MD, PhD
Publikationsdatum
13.01.2023
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 3-4/2023
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00996-1

Weitere Artikel der Ausgabe 3-4/2023

Wiener Medizinische Wochenschrift 3-4/2023 Zur Ausgabe